Xylem reports Q3 adjusted EPS $1.11, consensus $1.11

Reports Q3 revenue $2.1B, consensus $2.17B. “The team delivered strong results in the quarter, with earnings at the high end of guidance, and margin expansion beating our expectations,” said CEO Matthew Pine. “Demand remained resilient, reflected in robust orders growth in all segments, and a healthy book-to-bill. Moderated organic revenue growth in the quarter was driven largely by project timing. Outperformance on margin and earnings was further reinforced by momentum in our integration of Evoqua and by initial impacts from our broader simplification efforts,” Pine continued. “Evoqua integration is ahead of schedule and synergy capture continues to accelerate, giving us confidence in closing the year above target. As a result, we are narrowing our full-year earnings guidance, with continuing focus on sustainable, high-quality earnings and profitable growth.”